ARDELYX Q3 2026 EARNINGS - ARDELYX INC

Financial Performance:

• Total product revenue reached $125.5 million in Q3 2026, a 19% year-over-year increase from $105.5 million.
• Ibsrela (spelled "Ibsrell," "Ibsrella," "Avzrella," "Ibsirella" interchangeably in transcript) generated $96.3 million in revenue, up 23% YoY.
• Xfosa (also referred to as "Xfossa," "Exposa," "Xpota") generated $29.2 million in revenue, up 7% YoY, with paid prescriptions growing 22%.
• Net loss narrowed to $700,000 for Q3 2026, compared to $1.2 million in Q3 2025 (Note: Transcript mentions "$1 million" for prior year in one instance, later clarifies the current loss).
• Cash and short-term investments stood at $285.3 million; revenue is fully funding operations.
• Gross profit margin remains above 95%.
• Blended gross-to-net (GTN) rate for Q3 was 31.7%, slightly higher than 30.6% in the prior year, attributed to mix shifts and inflation rebates.
• Operating expenses were managed with R&D at $25.2 million (up from $18.1 million) and SG&A at $25 million (flat YoY).

Guidance and Future Outlook:

• Reaffirmed full-year 2026 Ibsrela revenue guidance of $350–$370 million, representing >30% mid-point annual growth.
• Reaffirmed full-year 2026 Xfosa revenue guidance of $110–$120 million.
• Confirmed full-year 2026 operating expenses will remain below $500 million.
• Company aims to achieve profitability in 2027, driven by revenue growth and disciplined expense management.
• Long-term goal for Ibsrela includes reaching $1 billion in annual revenue.
• Expect continued expansion of the pipeline anchored by Tenapenor, with Phase 3 EXCEL trial top-line results anticipated in H2 2027.

Business Segments and Product Lines:

• Ibsrela (IBS-C): Focus on eliminating payer friction; demand and HCP confidence at all-time highs. Expanded sales force and doubled field reimbursement management (FRM) teams. Launched first direct-to-consumer (DTC) ad campaign targeting 10M+ viewers; 91% of test patients indicated they would ask their doctor about the drug. Transitioning to the Ibsrela Pharmacy Network (IPN) to improve fulfillment rates (2-3x higher) and adherence.
• Xfosa (CKD): Serving 550,000+ US dialysis patients; 80% require treatment for hyperphosphatemia but 70% fail to reach targets. Revenue growth offset by sequential customer buying patterns and complex reimbursement environment.
• Pipeline: Tenapenor Phase 3 EXCEL trial for Chronic Idiopathic Constipation (CIC) fully enrolled ahead of schedule. Real-world data shows Ibsrela reduces GI healthcare resource utilization (fewer doctor visits/labs).

Market and Competitive Landscape:

• IBS-C market: Over 7 million prescriptions written annually for FDA-approved medications; >70% of patients have persistent symptoms.
• CIC market: Significantly larger than IBS-C; many patients cycle through OTC products and remain underserved.
• Competition: Ibsrela positioned as a differentiated alternative for IBS-C patients dissatisfied with IFC (likely a typo for IBS-C standard of care or similar) agents.
• Competitive advantage in CIC trial design based on clinical rationale and physician enthusiasm.

Risks and Challenges:

• Payer friction and prior authorization (PA) processes remain significant hurdles for new patient starts.
• Complex and evolving dialysis reimbursement environment impacts Xfosa's quarterly sequencing and revenue stability.
• Promotional sensitivity of the Ibsrela brand.
• Potential data discrepancies in prescription reporting due to the transition to the IPN (projected vs. 100% capture).
• Forward-looking statements carry risks related to clinical trial success, regulatory approvals, and market adoption.

Management Commentary and Tone:

• Tone is confident and execution-focused, emphasizing strong fundamentals despite external headwinds.
• Management stressed "thoughtful elimination" of friction rather than one-time fixes, utilizing AI, digital tools, and expanded FRM teams.
• CFO emphasized the company's strong liquidity and path to profitability in 2027.
• CEO expressed high confidence in the team's ability to execute and build the pipeline.
• Management declined to provide specific penetration rates for the IPN or specific prior authorization improvement metrics to avoid market disruption.

Analyst Questions and Answers:

• IPN Penetration: Management refused to disclose specific percentages of scripts flowing through the IPN, citing a need for a thoughtful transition.
• Long-term Xfosa Targets: Deferred long-term revenue framework discussion until the current turbulent reimbursement period (TDAPA) concludes.
• Payer Friction: Identified as a continuous challenge requiring a "panoply" of solutions (AI, payer negotiation, FRMs); not a one-time fix.
• CIC Market Opportunity: Estimated CIC market is significantly larger than IBS-C; Ibsrela targets patients who have failed OTC or current prescription therapies.
• Gross-to-Net for 2027: Management declined to comment on 2027 contracting strategies but confirmed current GTN is in the low-to-mid 30s.
• Pediatric Program: No updates provided on pediatric indications for Ibsrela.

Other Key Points:

• Real-world evidence presented at the American College of Gastroenterology meeting supports Ibsrela's ability to reduce healthcare resource utilization.
• Real-world evidence presented at the American Society of Nephrology Kidney Week highlights Xfosa's efficacy in reducing serum phosphate.
• The company is utilizing AI and digital tools to streamline prior authorization processes.
• Inventory levels at wholesalers were described as "just in time" with no significant overhang.
• The EXCEL trial enrollment speed underscores physician enthusiasm for a new CIC treatment option.